Anti-Parkinson’s Drugs Market Global Scenario, Market Size, Outlook, Trend, and Forecast, 2016 – 2025

TABLE OF CONTENTS

Chapter 1        Prefix

1.1    Market Scope

1.2    Report Description

1.3    Research Methodology

1.3.1     Primary Research

1.3.2     Secondary Research

1.3.3     In-house Data Modeling

Chapter 2        Executive Summary

2.1   Global Anti - Parkinson’s Drugs Market Year-on-Year Growth, 2020 – 2028 (%)

Chapter 3        Market Outline

3.1    Market Inclination, Trend, Outlook and Viewpoint

3.2    Market Share Analysis: Company’s Competitive Scenario

3.3    Value Chain Analysis

3.4    Porter’s Five Forces Analysis

3.5    Market Dynamics

3.5.1     Drivers

3.5.1.1     Impact Analysis

3.5.2     Restraints

3.5.2.1     Impact Analysis

3.5.3     Opportunities

Chapter 4        Global Anti - Parkinson’s Drugs Market by Drugs Class: Market Size and Forecast, 2019 – 2028

4.1    Overview

4.2  Levodopa

4.2.1   Current Trend and Analysis

4.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.2.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

4.3  Dopamine Receptor

4.3.1   Current Trend and Analysis

4.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.3.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

4.4  Monoamine Oxidase Type B Inhibitors

4.4.1   Current Trend and Analysis

4.4.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.4.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

4.5  Anticholinergics

4.5.1   Current Trend and Analysis

4.5.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.5.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

Chapter 5        Global Anti - Parkinson’s Drugs Market by Geography: Market Size and Forecast, 2019 - 2028

5.1  Overview

5.1.1   Global Anti - Parkinson’s Drugs Market Year-on-Year Growth, by region 2020 – 2028 (%)

5.2  North America

5.2.1   Current Trend and Analysis

5.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.3   U.S.

5.2.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.3.2        By Drug Class

5.2.4   Canada

5.2.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.4.2        By Drug Class

5.2.5   Mexico

5.2.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.5.2        By Drug Class

5.3    Europe

5.3.1   Current Trend and Analysis

5.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.3   UK

5.3.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.3.2        By Drug Class

5.3.4   Russia

5.3.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.4.2        By Drug Class

5.3.5   France

5.3.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.5.2        By Drug Class

5.3.6   Italy

5.3.6.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.6.2        By Drug Class

5.3.7   Germany

5.3.7.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.7.2        By Drug Class

5.3.8   Rest of Europe

5.3.8.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.8.2        By Drug Class

5.4    Asia-Pacific

5.4.1   Current Trend and Analysis

5.4.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.3   China

5.4.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.3.2        By Drug Class

5.4.4   India

5.4.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.4.2        By Drug Class

5.4.5   Japan

5.4.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.5.2        By Drug Class

5.4.6   Rest of Asia-Pacific

5.4.6.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.6.2        By Drug Class

5.5    RoW

5.5.1   Current Trend and Analysis

5.5.2   Market Size and Forecast

5.5.3   South America

5.5.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.5.3.2        By Drug Class

5.5.4   Middle East

5.5.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.5.4.2        By Drug Class

5.5.5   Africa

5.5.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.5.5.2        By Drug Class

Chapter 6        Company Profiles

6.1  Abbvie

6.1.1     Company Overview

6.1.2     Product Portfolio

6.1.3     Business Strategies

6.1.4     Financials

6.1.5     Recent Developments

6.2  Boehringer Ingelheim

6.2.1     Company Overview

6.2.2     Product Portfolio

6.2.3     Business Strategies

6.2.4     Financials

6.2.5     Recent Developments

6.3  Novartis AG

6.3.1     Company Overview

6.3.2     Product Portfolio

6.3.3     Business Strategies

6.3.4     Financials

6.3.5     Recent Developments

6.4  UCB SA

6.4.1     Company Overview

6.4.2     Product Portfolio

6.4.3     Business Strategies

6.4.4     Financials

6.4.5     Recent Developments

Back to top

Payment Options

Single User $3897
Five User $5175
Enterprise $9135
Datapack $1299
Short Report: $1799